randomized 1
phase 1
ii 1
trial 1
comparing 1
obinutuzumab 1
ga 1
rituximab 1
patients 1
relapsed 1
cd 1
indolent 1
bcell 1
nonhodgkin 1
lymphoma 1
final 1
analysis 1
gauss 1
study 1
